Annovis Bio Inc
ANVS
Company Profile
Business description
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Contact
101 Lindenwood Drive
Suite 225
MalvernPA19355
USAT: +1 484 875-3192
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,775.00 | 4.40 | 0.05% |
| CAC 40 | 7,742.24 | 57.56 | 0.75% |
| DAX 40 | 23,699.12 | 182.89 | 0.78% |
| Dow JONES (US) | 42,595.94 | 398.15 | 0.94% |
| FTSE 100 | 8,875.22 | 24.59 | 0.28% |
| HKSE | 24,060.99 | 168.43 | 0.70% |
| NASDAQ | 19,716.43 | 309.60 | 1.60% |
| Nikkei 225 | 38,311.33 | 477.08 | 1.26% |
| NZX 50 Index | 12,690.13 | 137.26 | 1.09% |
| S&P 500 | 6,040.62 | 63.65 | 1.06% |
| S&P/ASX 200 | 8,548.40 | 1.00 | 0.01% |
| SSE Composite Index | 3,388.73 | 11.73 | 0.35% |